Outcomes, challenges and prospects of emicizumab prophylaxis in Sub-Saharan Africa – Insights from the Tanzanian experience
By:
Authors
Rebbecca Wughanga Mwakichako
Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
Rajabu Hussein Mnkugwe
Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
Clara Chamba
Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
Peter Kunambi
Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
Martha Bruckman
Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
Anna Schuh
Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
Michelle Munroe
Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
Gladys Kaaya
Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
Mwashungi Ally
Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
Ahlam Nasser
Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
William Mawala
Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
Magdalena Lyimo
Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
Johnny Mahlangu
University of the Witwatersrand Johannesburg, Johannesburg, South Africa
Stella Rwezaula
Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
DOI: https://doi.org/10.2478/jhp-2025-0005 | Journal eISSN: 2055-3390
Language: English
Page range: 15 - 22
Published on: Mar 19, 2025
Published by: Haemnet Ltd
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year
Keywords:
Related subjects:
© 2025 Rebbecca Wughanga Mwakichako, Rajabu Hussein Mnkugwe, Clara Chamba, Peter Kunambi, Martha Bruckman, Anna Schuh, Michelle Munroe, Gladys Kaaya, Mwashungi Ally, Ahlam Nasser, William Mawala, Magdalena Lyimo, Johnny Mahlangu, Stella Rwezaula, published by Haemnet Ltd
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.